Topics:

Cervical Cancer

New HPV Vaccine Could Prevent 90% of Cervical Cancers

A new human papillomavirus (HPV) vaccine that protects against nine types of HPV and would protect against about 90% of cervical cancers could be available in 2015.

Cervical Cancer

Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.

A new study yielded nomograms for the assessment of locally advanced cervical cancer, with prognostic factors including histology, performance status, and others.

Cervical cancer survivors saw improvements in self-reported quality-of-life outcomes with a psychosocial telephone counseling intervention, according to a new study.

Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.

Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 is an appropriate treatment option for women aged 25 years and younger.

A test for dangerous strains of high-risk HPV using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification.

Multiple lesion-directed biopsies can drastically improve the sensitivity of colposcopy in women referred for abnormal cervical cancer screening.

Pages

Subscribe to Cervical Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.